Dr. Kelly is a scientific leader with both Pharma and Biotech experience and a track record of delivering high quality compounds into advanced clinical studies. He is expert in chemistry, disease biology and the enabling technologies needed for innovative and efficient drug discovery from lead identification through clinical development.
Between 1990 and 2009, Terry served in various scientific and executive positions at Boehringer Ingelheim, where after a successful early career developing LFA-1 antagonists, he led its US-based medicinal chemistry department. From 2010 – 2016 he was the CEO and CSO of CoMentis, Inc, and from 2019 to 2023 he served as President and CEO of Perception Neuroscience, a clinical stage biotech company developing small molecule therapeutics for mental health disorders. He is a founder of Kelly Pharma Research Consulting, LLC and served as a director of Cardax, Inc. between 2014 – 2021.
Terry holds a B.S. degree in Chemistry at Rensselaer Polytechnic Institute and a Ph.D. degree in Chemistry at the University of Texas at Austin. He completed postdoctoral work in natural products synthesis at Yale University (1988-1990) and holds an MBA from New York University. Dr. Kelly is the co-author of over 25 scientific publications and served on the College of Natural Sciences Advisory Council for the University of Texas.